drugset / Trial / NCT01074502
Apremilast in the Treatment of Moderate to Severe Acne
Phase 2
Terminated
3 enrolled
University of North Carolina, Chapel Hill
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
Acne is a chronic inflammatory disease of the pilosebaceous unit that affects 80-90% of the population, especially teenagers, although adult acne is a significant problem for 3-6 % of adult men and 5-12% of adult women. Although acne is not a life-threatening disease, it produces significant psychological disturbances and permanent skin scars. A novel anti-inflammatory, not antibiotic drug may be an excellent alternative for the treatment of moderate to severe acne. Apremilast has been shown to inhibit the production of tumor necrosis factor (TNF)-alpha, IL-8 and neutrophil infiltration, all of which are elevated in inflammatory acne. Our intention is to study Apremilast in the treatment of moderate to severe acne.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-07
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 20 mg | Oral |